Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017

Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017–2019

Published:2021-10-03 Issue:1 Volume:16 Page:151-158
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Choi Yoonyoung¹^ORCID,Hill‐Ricciuti Alexandra²,Branche Angela R.³,Sieling William D.²⁴,Saiman Lisa²⁵^ORCID,Walsh Edward E.³⁶,Phillips Matthew¹,Falsey Ann R.³⁶,Finelli Lyn¹

Affiliation:

1. Center for Observational and Real‐World Evidence, Merck & Co., Inc. Kenilworth New Jersey USA

2. Department of Pediatrics Columbia University Irving Medical Center New York New York USA

3. Department of Medicine, Division of Infectious Diseases University of Rochester Rochester New York USA

4. Department of Medicine University of Minnesota Medical School Duluth Campus Duluth Minnesota USA

5. Department of Infection Prevention & Control NewYork‐Presbyterian Hospital New York New York USA

6. Rochester General Hospital Rochester New York USA

Funder

Merck Sharp and Dohme

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12912

Reference26 articles.

1. Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012

2. Acute respiratory illness in the community. Frequency of illness and the agents involved

3. Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults

4. Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017–2020

5. The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adult Respiratory Syncytial Virus Infection: Defining Incidence, Risk Factors for Hospitalization, and Poor Outcomes, a Regional Cohort Study, 2016–2022;Pathogens;2024-08-31

2. A fieldable process for sensitive detection of airborne viruses via electrophoresis-based RNA enrichment;Biosensors and Bioelectronics: X;2024-08

3. Economic burden of cardiorespiratory hospitalizations associated with respiratory syncytial virus among United States adults in 2017–2019;Human Vaccines & Immunotherapeutics;2024-07-09

4. Respiratory Virus-Induced PARP1 Alters DC Metabolism and Antiviral Immunity Inducing Pulmonary Immunopathology;Viruses;2024-06-04

5. The respiratory syncytial virus vaccines are here: Implications for solid organ transplantation;American Journal of Transplantation;2024-06